Navigation Links
FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery
Date:2/1/2012

r treatment period in the 36-month group and 13% in the 12-month group(1).

Novartis provided the study drug and supported the study financially. Additional funding was received from the Academy of Finland, Cancer Society of Finland, Sigrid Juselius Foundation and Helsinki University Research Funds.

About Gleevec
Gleevec® (imatinib mesylate) tablets are indicated for the treatment of patients with KIT (CD117)-positive gastrointestinal stromal tumors (GIST) that are cancerous, cannot be surgically removed, and/or have spread to other parts of the body. Gleevec is also approved for use after surgery in patients that have had their KIT (CD117)-positive GIST completely removed.

Gleevec Important Safety Information
Gleevec can cause fetal harm when administered to a pregnant woman. Women taking Gleevec should not become pregnant, and should be advised of the potential risk to the unborn child.

Gleevec is often associated with edema (swelling) and serious fluid retention. Studies have shown that edema (swelling) tended to occur more often among patients who are 65 and older or those taking higher doses of Gleevec.

Cytopenias (reduction or lack of certain cell elements in blood circulation), such as anemia, have occurred. If the cytopenia is severe, your doctor may reduce your dose or temporarily stop your treatment with Gleevec.

Severe congestive heart failure and left ventricle dysfunction have been reported, particularly in patients with other health issues and risk factors. Patients with heart disease or risk factors or history of renal failure will be monitored and treated for the condition.

Severe liver problems (hepatotoxicity) may occur. Cases of fatal liver failure and severe liver injury requiring liver transplants have been reported with both short-term and long-term use of Gleevec.

Bleeding may occur. Severe gastrointestinal (GI) bleeding has been reported in
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)...  Kastle Therapeutics (Kastle), a biopharmaceutical company focused ... with high unmet medical needs, announced today that ... operating positions. Sean McAuliffe ... previously Global Marketing Director for Baxalta. Nick ... Strategy and Analytics; Nick was previously Director, Forecasting ...
(Date:9/2/2015)... , Sept. 2, 2015  OncoSec Medical Incorporated ... intratumoral cancer immunotherapies, announced today that members of its ... events in September, including: , First ... Biology, Medicine and Food & Environmental Technologies; Portoroz, ... 17th Annual Global Investment Conference; New York, ...
(Date:9/1/2015)... , September 2, 2015 ... for global clinical trials review of H2, 2015 ... with an objective to enhance decision making capabilities ... Complete report on Keratoconus market clinical trials review ... 10 institutes / government organizations and supported with ...
Breaking Medicine Technology:Kastle Therapeutics Announces Key Additions to Commercial Leadership 2Kastle Therapeutics Announces Key Additions to Commercial Leadership 3OncoSec to Present at Scientific and Investment Conferences in September 2OncoSec to Present at Scientific and Investment Conferences in September 3OncoSec to Present at Scientific and Investment Conferences in September 4OncoSec to Present at Scientific and Investment Conferences in September 5Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 2Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 3Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 4Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 5
(Date:9/2/2015)... ... September 02, 2015 , ... ... endpoint data collection, cloud analytics and workflow solutions today announced the September ... pharmaceutical researchers to participate in interactive programs in which ERT scientists and ...
(Date:9/2/2015)... ... September 02, 2015 , ... RxNT , ... launch of its enhanced, cloud-based mobile ePrescribing application. The release of this enhanced ... prescriber usability. A leader in health technology, RxNT was one of the first ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... Affairs Officer following the departure of Kristen Dietz, former Chief Operations Officer. ... released the following statement welcoming Mr. Salot: “ Stanley H. Salot Jr , ...
(Date:9/2/2015)... ... September 02, 2015 , ... Splashtop Inc., the worldwide leader ... screen mirroring and extending product line -- Splashtop Wired XDisplay . ... WIFI setting, the new Splashtop Wired XDisplay delivers enhanced performance and reliability for ...
(Date:9/2/2015)... ... September 02, 2015 , ... Care Providers and their ... documents that include EOBs, payments, and payment related documents. AD-EOB A/R helps them ... reconcile their billing, with one efficient process and interface,“ stated Rich Caproni, AliusDoc’s ...
Breaking Medicine News(10 mins):Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 2Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 3Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2Health News:Healtec® Announces Executive Leadership Change 2Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 2Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 3Health News:AliusDoc Launches Enhanced AD-EOB A/R Data Capture Solution to Streamline Processing of Payment-Related Documents Together with EOBs 2
... groups were thought to be rare, but recent studies ... the thin beauty ideal. As a result, experts expect ... ethnic groups. It is also suspected that eating disorders ... boys. Although research has shown that eating disorders ...
... of the Charmin Restrooms to ... Times Square This Holiday Season, NEW YORK, Nov. ... free, fully-staffed public restrooms,in New York City as the Charmin(R) Restrooms ... Shannon will inaugurate the stalls,with the ceremonial "first flush" and ribbon ...
... Family Caregiver,s Month; Announces Availability ... More than 34 Million Caregivers, PALO ALTO, Calif., Nov. ... proud to support the more than 34 million,Americans caring for ... availability of its website. Designed to give caregivers the ...
... Flow Cytometry Portfolio Targeted at Fast Growing ... ... Nov. 19, Beckman Coulter, Inc. (NYSE: BEC ), a leading,developer ... A/S, a world leader in cancer diagnostics,announced today that Beckman Coulter ...
... REDWOOD CITY, Calif., Nov. 19 People grow ... is no different. SleepQuest, the leader in,at-home diagnostic ... growing pains which accompany rapid growth by moving ... INC. Magazine,s 5000 Fastest Growing Private,Companies in America, ...
... GNC is joining St. Jude Children,s,Research Hospital as ... is the fourth year for the national campaign and ... in the effort. Thanks and Giving was created ... Thomas and her siblings, Terre and Tony,Thomas, the children ...
Cached Medicine News:Health News:Eating disorders in adolescents 2Health News:Eating disorders in adolescents 3Health News:Video: Charmin's Gift That Keeps on Giving! 2Health News:Resource to Help Care for Aging Parents Now Available Nationwide 2Health News:Resource to Help Care for Aging Parents Now Available Nationwide 3Health News:Beckman Coulter to Acquire Flow Cytometry Instrumentation Business From Dako 2Health News:Beckman Coulter to Acquire Flow Cytometry Instrumentation Business From Dako 3Health News:SleepQuest Continues Growth, Moves Headquarters 2Health News:GNC Joins St. Jude Children's Research Hospital(R) to Kick Off Fourth Annual Thanks And Giving(R) Campaign, Asking America to Help Save Children's Lives While Shopping for the Holidays 2Health News:GNC Joins St. Jude Children's Research Hospital(R) to Kick Off Fourth Annual Thanks And Giving(R) Campaign, Asking America to Help Save Children's Lives While Shopping for the Holidays 3
Stryker Endoscopy offers a superior selection of probes and tips that interface with our suction and irrigation system....
The new PERIMOUNT Magna heart valve (bioprosthesis), with its true supra-annular design, offers optimal hemodynamics and flow characteristics for treatment of aortic heart valve disease....
... revolutionary flexibility to floor-mounted X-ray systems. ... move the C-arm around the exam ... optimal angle for cardiac and general ... cardiac flat panel detector that delivers ...
... pH.p Capsule passes through the GI tract, it ... frequencies to the SmartPill Data Receiver, a small, ... the patient (supported by either a belt or ... and pH measurement data, and elapsed and real ...
Medicine Products: